



Intranasal inoculations of naked or PLGA-PEI nanovectored DNA vaccine induce systemic and mucosal antibodies in pigs: A feasibility study

Laurent Souci, Hervé Jaunet, Gérald Le Diguerher, Jean-Marie Guionnet, Véronique Béven, Frédéric Paboeuf, Tristan Montier, Daniel Dory

► To cite this version:

Laurent Souci, Hervé Jaunet, Gérald Le Diguerher, Jean-Marie Guionnet, Véronique Béven, et al.. Intranasal inoculations of naked or PLGA-PEI nanovectored DNA vaccine induce systemic and mucosal antibodies in pigs: A feasibility study. *Research in Veterinary Science*, 2020, 132, pp.194-201. 10.1016/j.rvsc.2020.06.018 . hal-03093878

HAL Id: hal-03093878

<https://hal.inrae.fr/hal-03093878>

Submitted on 15 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

**Intranasal inoculations of naked or PLGA-PEI nanovectored
DNA vaccine induce systemic and mucosal antibodies in pigs: a
feasibility study**

**Laurent Souci ^{1,a}, Hervé Jaunet ², Gérald Le Dignerher ³, Jean-Marie Guionnet ³,
Véronique Béven ¹, Frédéric Paboeuf ³, Tristan Montier ⁴, Daniel Dory ^{1, *}**

¹ French Agency for Food, Environmental and Occupational Health & Safety (ANSES),
Viral Genetics and Biosafety Unit, Ploufragan, France

² ZOOPOLE Development, Ploufragan, France

³ French Agency for Food, Environmental and Occupational Health & Safety (ANSES),
Pig Production and Experimental Unit, Ploufragan, France

⁴ SynNanoVect platform - UMR INSERM 1078, University of Brest, Brest, France

* Corresponding author: Daniel Dory. ANSES, Ploufragan/Plouzané Laboratory, Viral
Genetics and Biosafety Unit, BP 53, 22440 Ploufragan, France.

Tel.: +33 2 96 01 64 42; Fax: +33 2 96 01 62 83.

E-mail: daniel.dory@anses.fr

^a Present address: INRAE, Biology of Avian Viruses team, Nouzilly, France

Abstract:

Mucosa are the routes of entry of most pathogens into animals' organisms. Reducing the important global burden of mucosal infectious diseases in livestock animals is required in the field of veterinary public health. For veterinary respiratory pathogens, one possible strategy is the development of intranasal (IN) DNA vaccination. The aim of this study was to assess the feasibility of IN DNA vaccination in pigs, an important species in livestock production industry, and a source of zoonotic diseases. To achieve this goal, we used a DNA vaccine against pseudorabies virus (PrV) encoding the immunogenic glycoprotein B (pcDNA3-gB plasmid). When pigs were inoculated with the naked DNA vaccine through the IN route, PrV-specific IgG and IgA type antibodies were detected in porcine sera. Interestingly, mucosal salivary IgA antibodies against PrV were also detected, at similar levels to those measured following intramuscular injection (positive controls). Furthermore, the IN delivery of pcDNA3-gB combined with PLGA-PEI nanoparticles resulted in similar levels of antibodies but was associated with an increase in the duration of detection of mucosal IgA for 2 out of 3 pigs. Our results suggest that there is room to improve the efficacy of IN DNA vaccination in pigs through optimization of IN inoculations, for example by using nanoparticles such as PLGA-PEI. Further studies will be dedicated to optimizing and testing the protective potential of IN DNA vaccination procedures against PrV.

Keywords: DNA vaccination; swine; intranasal; antibodies; salivary IgA

1. Introduction

Respiratory pathogens of livestock animals are responsible for high economic losses for farms due to high morbidity and sometimes lethal respiratory diseases. In some rare cases,

animal pathogens can be transmitted and emerge in humans, as exemplified with the 2009 H1N1 influenza pandemic of swine origin (Hass et al., 2011). It is therefore necessary to develop strategies to control animal infections, and vaccination represents one of the most powerful tools available. Vaccines administered via the systemic route are often effective in inducing broad and heterologous protective immunity, but there are exceptions. In these cases, like for vaccination against swine influenza or porcine reproductive and respiratory syndrome (Dhakal and Renukaradhya, 2019), mucosal vaccination may be beneficial. Because respiratory pathogens enter the body through the respiratory mucosa, induction of mucosal protective immune responses may limit entry of the pathogens and associated infection (Kraehenbuhl and Neutra, 2013). Mucosae are located in various cavities of the body, at the interface between the external and internal environments (*e.g.* respiratory or gastrointestinal tracts). They contribute to essential functions such as respiration, nutrition, and reproduction, while playing a protective role by preventing the physical entry of pathogens (Liebler-Tenorio and Pabst, 2006), and by mobilizing the innate and specific local immune systems (Lawson et al., 2011; Liebler-Tenorio and Pabst, 2006; Lycke, 2012; Pabst, 2012). Moreover, a key part of mucosal immunity is mucosa-associated lymphoid tissues (MALTs), that are functionally interconnected despite being anatomically separated, thus allowing protection through IgA secretion can reach a broad range of distant mucosal surfaces (McGhee and Fujihashi, 2012).

Most mucosal vaccination strategies involve the oral or nasal routes. Most mucosal vaccines consist of attenuated pathogens, with no or very low virulence (Lycke, 2012; Pavot et al., 2012) that mimic as much as possible the wild-type pathogens they are derived from and can therefore enter the organism through the mucosa. Because these viruses remain alive, reversion to virulence or interactions with other pathogens present at the time of inoculation have been reported (Eclercy et al., 2019; Liu et al., 2018). Therefore, as a safety measure, it is recommended to develop subunit vaccines. For example, vaccine antigens can be inserted

75 into viral or bacterial vectors, be administered as recombinant proteins (Wang et al., 2015) or
76 as DNA vaccines (Farris et al., 2016; Oh et al., 2001). Among those, the DNA vaccine
77 strategy presents many advantages, the main one being its simplicity. DNA vaccination
78 consists in inoculating plasmid DNA encoding the vaccine antigen. These antigens are then
79 produced in the vaccinated animals, inducing humoral and cellular immune responses
80 (Dufour, 2001). In addition, DNA vaccines are non-infectious, easy to develop and to
81 produce in high quantities, and they induce an immune response different from that of natural
82 infection allowing differentiation of infected and vaccinated animals (DIVA). DNA
83 vaccination has successfully been achieved in the veterinary field and several vaccines are
84 available on the market (Clynav[®], West Nile Innovator[®], Apex-IHN[®] and Oncept[®] vaccines)
85 (Dalmo, 2018). For intranasal (IN) DNA vaccination, the vaccine is either be inoculated in its
86 naked form (Gomes et al., 2007) or combined with vectors (liposomal or
87 nano/microparticulate structures) that serve as mucosal delivery systems (Csaba et al., 2009).
88 It was previously shown in rodents that such nanovectors can protect the vaccine DNA from
89 mucosal degradation and favor interaction with mucosal cells, antigen-presenting cells
90 (APCs) or inductive sites of MALTs (Kraehenbuhl and Neutra, 2013). The two most
91 common biopolymers, described for IN DNA vaccination purposes, are chitosan (Khatri et
92 al., 2008) and poly(lactic-co-glycolic) acid (PLGA) (Du et al., 2015). In particular, PLGA
93 has been optimized for a more efficient delivery and internalization of the DNA vaccine by
94 mucosal surfaces (*e.g.* nasal cavity). For example, the combination of polyethylenimine
95 (PEI) with PLGA enhances electrostatic interactions of PLGA with DNA plasmids (thanks to
96 cationic nature of the PEI) and promotes its interaction with mucosal cells, and no cell
97 cytotoxicity was reported (Shau et al., 2012). However, it is important to point out that the
98 vast majority of IN DNA vaccine studies were performed using mice or guinea pigs (Ai et al.,
99 2013; Du et al., 2015; Iqbal et al., 2003; Khatri et al., 2008; Nanda et al., 2014). Given the
100 importance of respiratory pathogens in the veterinary field, and associated risks for zoonotic

diseases, there is a strong need to conduct new studies to determine the efficacy of IN DNA vaccination for livestock animals such as pigs.

Given that the respiratory tract is the most common route of viral entry, IN DNA vaccination strategies represent a novel and promising vaccination strategy. The pseudorabies virus (PrV) that uses nasal cells as a route of entry into the pig body (Babic et al., 1994) is an ideal viral model to test IN DNA vaccination in pigs. Also, intramuscular DNA vaccination is effective and can be used as positive control (Dory et al., 2005; Gerdtts et al., 1997). Among the glycoproteins encoded by the PrV DNA vaccine, the glycoprotein B (gB) is of particular interest because it is highly immunogenic (Dory et al., 2009) and could be used to validate new DNA vaccine strategies. This protein has previously been used in our laboratory to evaluate the potential of electroporation for porcine DNA vaccination (Le Moigne et al., 2012).

In the present study, the plasmid encoding PrV-gB (pcDNA3-gB) associated with a plasmid pcDNA3-GM-CSF encoding granulocyte macrophage colony stimulating factor (GM-CSF used as an adjuvant (Somasundaram et al., 1999)) was administered intranasally in its naked form or associated with the nanovector PLGA-PEI. Naked DNA IN inoculation resulted in mucosal salivary IgA antibodies production. Furthermore, the vectored DNA vaccine appeared to extend the duration of IgA production compared to naked DNA alone. These promising results justify further studies to optimize IN DNA vaccination in pigs to prevent infectious respiratory diseases.

2. Materials and Methods

2.1 Plasmids

Plasmids pcDNA3-gB (encoding PrV-gB) (Dory et al., 2009), pcDNA3-GM-CSF (encoding granulocyte macrophage colony stimulating factor) (Somasundaram et al., 1999), and pTG11033 (encoding luciferase) (Lindberg et al., 2015) were produced in *E. coli* and

purified using a Maxiprep plus endotoxin-free DNA extraction kit (Macherey-Nagel, Germany), according to the manufacturer's instructions. The plasmids were resuspended in endotoxin-free tris-EDTA buffer. Plasmid concentrations and purities were assessed spectrophotometrically by measuring OD ratios at 260 nm/280 nm, and 260 nm/230 nm, respectively (Plate reader infinite 200 Pro, TECAN Ltd, Switzerland).

2.2 Preparation of plasmid-PLGA-PEI nanoparticles

PLGA-PEI nanoparticles were purchased from NanoVex Biotechnologies (Spain). The sizes of the particles were 200 ± 12 nm and the zeta potentials were 38.9 ± 0.4 mV. plasmid-PLGA-PEI nanoparticles were obtained by the adsorption of plasmid DNA onto PLGA-PEI surfaces, as previously described (Shau et al., 2012). Briefly, plasmid DNA and PLGA-PEI were diluted into ultrapure water and mixed at a weight DNA/weight PEI ratio of 12, vortexed for 30 sec and incubated for one hour at room temperature (RT). Freshly prepared nanoparticles were inoculated or studied *in vitro* within hours.

2.3 Assessment of humoral immune responses after IM injection or IN inoculation of a naked PrV-gB-based DNA vaccine

All the experimental protocols described in this paper were approved by the ethics committee for animal experimentation of ANSES/National Veterinary School of Alfort/University of Paris-Est Créteil (France) (Notice number 10/07/18-3), and by the French Ministry of Research under reference 15614-201806210855647_v2.

Two groups of 8–9-week-old specific pathogen-free (SPF) pigs were inoculated three times at 10-day intervals (**Fig. 1A**). They weighed 24.5 ± 2.9 kg at the time of the first inoculation. Pigs in group #1 (n=3 pigs) were injected with 4 mL of the DNA vaccine

composed of 400 µg of pcDNA3-gB and 100 µg of pcDNA3-GM-CSF by the IM route in the neck muscle. pcDNA3-GM-CSF was used as an adjuvant, as previously described (Somasundaram et al., 1999). Pigs in group #2 (n=3 pigs) were inoculated with the same DNA vaccine by the IN route (2 mL in each nostril) using an MAD100 Nasal™ Intranasal Mucosal Atomization Device (Teleflex Medical, Wayne, USA). Non-inoculated control pigs made up an additional group, group #3 (n=2 pigs). All pigs were observed daily to detect any adverse reactions. Body temperatures were measured daily and pigs were weighed weekly. Blood sera were collected on days 0, 10, 20, 29 and 37 post-inoculation (pi). Salivary samples were collected on days 29 and 37 pi. On day 38 pi, pigs were anesthetized with an auricular intravenous injection of thiopental (1 g/50 kg body weight) and euthanized. All the organs and the snout of each pig were observed during the autopsies to detect any problem linked to inoculations.

2.4 Assessment of humoral immune responses after IN inoculation of naked or nanovectored PrV-gB-based DNA vaccines

Four groups of 7–8-week-old SPF pigs were inoculated three times at 10-day intervals (**Fig. 1B**). They weighed 25.9 ± 5.7 kg at the time of the first inoculation. Three groups of three pigs were inoculated by the IN route using an MAD100 Nasal™ Intranasal Mucosal Atomization Device (Teleflex Medical, Wayne, USA) with 300 µg of pcDNA3-gB + 100 µg of pcDNA3-GM-CSF (2 mL corresponding to half of the DNA vaccine in each nostril). Pigs in groups #1 and #2 were inoculated with naked pcDNA3-gB and PLGA-PEI-pcDNA3-gB, respectively. One control pig (group #3) was injected three times at the same time points with the same naked DNA vaccine (4 mL in total) by the IM route. Finally, an additional group of four non-inoculated pigs served as negative controls (group #4). Clinical observations and euthanasia were performed as described above, except that euthanasia was performed on day 50 pi. Blood sera were collected the day before the first inoculation and on days 9, 20, 27, 37,

44 and 50 pi. Salivary samples were collected the day before the first inoculation and on days 10, 20, 30, 37 and 44 pi.

2.5 Determination of serum anti-PrV IgG and IgA antibody titers

An indirect ELISA for the determination of serum anti-PrV-specific IgG and IgA antibody titers was adapted from the protocol previously described (Le Moigne et al., 2012). Briefly, maxiSorp 96-well plates (Nunc, ThermoFisher, USA) were coated overnight with 1.5 µg/well of PrV glycoproteins diluted in 100 µL of 0.05 M carbonate buffer (Sigma-Aldrich, USA) at 4°C. The plates were washed twice with phosphate buffered saline (PBS) buffer pH 7.4 containing 0.05% tween 20 (PBS-T, Sigma-Aldrich, USA) prior to being blocked with 300 µL/well of blocking buffer [1% BSA (Eurobio, France) in PBS-T] for two hours at 37°C. After two washes with PBS-T, the plates were incubated for 1 h at 37°C with 100 µL/well of two-fold serial diluted serum samples in PBS-T. Each serum sample was analyzed in triplicate. After three washes, the plates were incubated for 1 h at 37°C with 100 µL/well of 1:20,000 diluted horseradish peroxidase (HRP)-conjugated goat anti-pig IgG (H/L) (Bio-Rad, USA) or 1:100,000 diluted HRP-conjugated goat anti-pig IgA AAI40P antibody (Bio-Rad, USA) for IgG or IgA determinations, respectively. These antibodies were diluted in 1% BSA/PBS-T. Finally, after three washes, 100 µL/well of tetramethylene benzidine (TMB) substrate (Pierce TMB substrate kit, ThermoFischer Scientific, USA) was added to the plates for 5 or 10 min for IgG or IgA determinations, respectively. The reactions were stopped by adding 100 µL/well of 2 M sulphuric acid (H₂SO₄, Sigma-Aldrich, USA). The plates were shaken for 1 min and the absorbance at 450 nm of each well was read on an Infinite 200 Pro plate reader (TECAN Ltd, Switzerland). Antibody titers were expressed as the highest dilution giving an OD value higher than the threefold OD of the control sera from the non-vaccinated and non-infected pigs.

2.6 Determination of salivary anti-PrV IgA antibody titers

An indirect ELISA was performed on salivary samples in triplicate as described above for the serum samples, with minor modifications. 1:150,000 diluted AAI40P HRP-conjugated goat anti-pig IgA antibody and 15 min of incubation with the TMB-substrate were used.

2.7 *In vitro* characterization of the nanovectored plasmids

The plasmids were characterized as previously described, with some modifications (Berchel et al., 2015; Le Gall et al., 2013). Twenty thousand cells/well of human bronchial epithelial cells (HBE-16) were incubated in 96-well plates overnight (37°C, 5% CO₂) with Eagle's minimal essential medium (EMEM) supplemented with 1% penicillin/streptomycin antibiotics, 1% glucosamine (Gibco, ThermoFisher, USA) and 10% fetal bovine serum. Then, the cells were incubated in triplicate for 72 hours with 40 µL/well of either naked pTG11033 plasmid or PLGA-PEI-pTG11033. Controls consisted of EMEM or of PLGA-PEI without DNA. Thereafter, the cultures were assessed for cytotoxic effects and the transfection potential of each DNA or nanovector preparation.

2.7.1 Cytotoxic effect evaluation

Each preparation described above was evaluated for cytotoxic effects on cell supernatants using a CytoTox 96® Non-Radioactive Cytotoxicity Assay kit, according to the manufacturer's instructions (Promega, USA).

2.7.2 Transfection potential evaluation

After removing the remaining culture medium, 75 µL/well of passive lysis buffer (PLB buffer, Promega, USA) were added. Then, 25 µL of each cell lysate were transferred to two separates plates. The first plate (a transparent MaxiSorp 96-well plate, Nunc, Naperville,

USA) was used to determine total protein content using a BC Assay kit, according to the manufacturer's instructions (Pierce, ThermoFisher, USA). The other plate (a white MaxiSorpLumiNunc 96-well plate, Nunc, USA) was used to measure luciferase activities using the Promega Firefly Luciferase Assay System (Promega, USA), according to the manufacturer's instructions. An amount of 65 μ L per well of Promega Luciferase Assay Reagent was added. After 2 min incubation at RT in the dark, the luminescence was measured with a luminescence Infinite 200 Pro plate reader (TECAN Ltd, Switzerland), with reading and delay times of one second each. The results were expressed as relative light units (RLUs) per milligram of total proteins.

2.8 Statistical analyses

For the *in vitro* experiments, a Mann–Whitney–Wilcoxon (U) test (non-directional test) was used. Comparisons were performed at a limit of significance of 0.05.

3. Results

3.1 PrV-specific systemic and mucosal humoral responses induced after IN inoculation of the naked PrV-gB-based DNA vaccine (pig experiment #1)

Two groups of three pigs were inoculated three times at ten-day intervals with a naked pcDNA3-gB-based DNA vaccine either through the IM or IN route, respectively (**Fig. 1A**). A third group of two pigs was not inoculated and served as a control group. None of the DNA inoculated pigs had fever, showed side effects, and they all grew similarly to the non-inoculated animals for the duration of the experiment. At necropsy, no lesions related to the inoculation or injection procedures were observed.

3.1.1 Determination of serum anti-PrV IgG and IgA following IM or IN inoculation of the naked PrV-gB-based DNA vaccine

In previous studies, we showed that pcDNA3-gB when inoculated intramuscularly induced strong production of systemic anti-PrV IgG antibodies (Dory et al., 2009; Le Moigne et al., 2012). Here, as expected, the three pigs injected with the PrV-gB-based DNA vaccine by the IM route exhibited an elevated serum anti-PrV IgG response that started to be detected on day 20 pi (10 days after the second injection), and the response remained high or increased after the third injection until the end of the pig experiment (**Fig. 2A**). Maximum titers expressed in log2 base were between 13.5 (pigs #2 and #3) and 15.2 (pig #1). Serum anti-PrV IgA antibodies started to be detected on day 10 pi for pig #1, and on day 20 pi for the other two pigs (**data not shown**). The highest titers were observed on day 29 pi (between 6.3 and 7.3 log2). The two non-inoculated pigs produced no anti-PrV IgG and IgA (**Fig. 2A and data not shown**).

For the group inoculated by the IN route with the naked PrV-gB-based DNA vaccine, pig #3 produced IgG antibodies against PrV from 20 days pi to the end of the pig experiment (**Fig. 2B**). On day 37 pi, the titer was 9.3 log2 for this pig. Pig #2 in this group also exhibited an increasing level of PrV-specific serum IgG response, but it started only after the third inoculation (day 29 pi). It reached a titer of 6.3 log2 at the end of the pig experiment (37 dpi). For the third pig (pig #1), a transient and very low response was observed only on day 29 pi (4.4 log2). Concerning the induction of systemic anti-PrV IgA, pig #1 elicited such a response from 20 dpi (highest titer of 6.3 log2 on day 20 pi) (**data not shown**). The other two pigs showed only a slight increase of the titer on day 37 pi (3.1 log2) (**data not shown**).

3.1.2 Determination of anti-PrV sIgA in the saliva of pigs following IM or IN inoculation of the naked PrV-gB-based DNA vaccine

Thereafter, the presence of anti-PrV sIgA was determined in pig saliva collected on days 29 and 37 pi (**Fig. 3**). No antibodies were detected in the samples from the two non-inoculated pigs. Antibodies were detected in two out of three pigs injected by the IM

route with the naked DNA vaccine. The titers of antibodies were 3.4 and 4.3 log 2, respectively. More interestingly, all the pigs inoculated through the IN route with the naked PrV-gB-based DNA vaccine had sIgA titers against PrV at least at the same order of magnitude as those of the pigs injected through the IM route with the same vaccine. Furthermore, pig #2 presented higher titers than those detected in the IM group (titers of 7.3 and 6.3 log₂ on days 29 and 37 pi, respectively).

3.2 PrV-specific systemic and mucosal humoral responses induced after IN inoculation of the PLGA-PEI-nanovectored DNA vaccine encoding PrV-gB (pig experiment #2)

In previous studies, researchers have used nanovectors to protect DNA vaccines from mucosal degradation. In the second part of this study, the PrV-gB-based DNA vaccine was associated with PLGA-PEI already known to enhance DNA vaccine efficacy, mainly in mice experiments.

3.2.1 *In vitro* characterization of the nanovectored DNA plasmids

The PLGA-PEI nanovectored DNA plasmids encoding luciferase were prepared as described above and incubated for 72 hours with the bronchial epithelial cell line HBE-16. Cytotoxic analyses performed on the supernatants of these cell cultures revealed that the preparation with PLGA-PEI had no toxicity for the cells (**Fig. 4A**). Furthermore, only the association of PLGA-PEI with the plasmid DNA encoding luciferase enabled the expression of luciferase within the cells (**Fig. 4B**). These results indicate that the nanovectors composed of PLGA-PEI are functional and can be safely administered to pigs.

3.2.2 Determination of serum anti-PrV IgG and IgA following IN inoculation of the PLGA-PEI-nanovectored PrV-gB-based DNA vaccine

Two groups of three pigs were intranasally inoculated three times at ten-day intervals with the naked PrV-gB-based DNA vaccine or PLGA-PEI PrV-gB-based DNA vaccine, respectively. As a control, an additional pig was intramuscularly injected at the same time points with the naked DNA vaccine. Finally, a fourth group of four non-inoculated pigs was added. No adverse reactions following any of the inoculations were observed throughout the pig experiment. Humoral immune responses against PrV were measured until day 50 pi (**Fig. 1B**).

Specific IgG and IgA titers against PrV were measured in the sera of all the pigs every 7-10 days throughout the pig experiment. Confirming results from experiment #1 described above, anti-PrV IgG and IgA were detected in the sera of the pigs inoculated with the naked DNA vaccine through the IM (**data not shown**) and IN routes (**Fig. 5A for IgG and data not shown for IgA**). For the pigs inoculated with the PLGA-PEI-DNA vaccine, the systemic anti-PrV IgG and IgA immune responses was low for all three pigs (**Fig. 5B and data not shown, respectively**).

3.2.3 Determination of anti-PrV sIgA in the saliva of pigs inoculated with nanovectored pcDNA3-gB through the IN route

Compared to experiment #1, saliva was collected for a longer period from day 0 until day 44 pi (instead of only days 29 and 37 pi as in the first pig experiment). sIgA against PrV was detected in most of the pigs inoculated with the DNA vaccine after the second or third inoculation (naked DNA vaccine injected through the IM route (**Fig. 6A**) or inoculated through the IN route (**Fig. 6B**) and nanovectored PLGA-PEI-DNA vaccine (**Fig. 6C**)). However, for the majority of the pigs, the detection of these antibodies was transient since on day 44 pi, these antibodies were no longer detected (**Fig. 6A, 6B and pig #2 of Fig 6C**).

There was two notable exceptions: sIgA against PrV was still detected in saliva in pigs #1 and #3 in the PLGA-PEI DNA vaccine group on day 44 pi (titers of 3.3) (**Fig. 6C**).

4. Discussion

There is a need to develop new vaccine strategies against respiratory pathogens in pigs. Very promising results for IN DNA vaccination have been obtained using mice or guinea pigs (Ai et al., 2013; Du et al., 2015; Iqbal et al., 2003; Khatri et al., 2008; Nanda et al., 2014). Of specific interest, IN inoculation to mice of a naked plasmid encoding the same PrV-gB as the one used in the present study resulted in the induction of vaginal PrV-specific sIgA, but not in protection (Yoon et al., 2008). Unfortunately, there are very few data on mucosal DNA vaccination in large animals, and none on IN DNA vaccination in pigs. Furthermore negative results are common. For example, a DNA vaccine against the foot-and-mouth disease virus (FMDV) was not efficient in sheep when administered through the IN route, regardless of whether the vaccine was naked or not (Niborski et al., 2006).

The present study aims at generating preliminary results on the development of IN DNA vaccination in pigs. To do this, we used a DNA vaccine against PrV that induces immune responses after IM injection: a DNA vaccine encoding PrV gB (Dory et al., 2009; Le Moigne et al., 2012). This model is especially valuable for such study because (1) the virus enters the body through the nasal route (and therefore it is beneficial to generate protective immunity at this entry site), and (2) it has been shown that a plasmid encoding PrV-gB induced the production of mucosal sIgA against PrV in the vagina after IN inoculation of mice (Yoon et al., 2008). It can thus serve as a marker of induction of systemic and mucosal humoral immune responses to study new strategies to inoculate DNA vaccines in pigs. At this stage, it has to be pointed out that PrV-gB alone is not able to induce strong protective immunity against PrV-infection in pigs (van Rooij et al., 2000),

and this was also the case after IN inoculation in mice (Yoon et al., 2008). Therefore, PrV-gB is fully adapted to the study we wanted to perform here since the main aim of the present study was first to evaluate if IN inoculation of a DNA vaccine can induce the production of immune responses, and more particularly mucosal immune responses. For this reason, and because they are beyond our objective, protective studies were not conducted. Before a PrV-challenge with a protective DNA vaccine encoding PrV-gB, -gC and -gD (Dory et al., 2005; Gerdtz et al., 1997; van Rooij et al., 2002) could be designed in pigs, IN administration of DNA vaccine must first be optimized.

In the present study, the IM route of immunization served (1) to show that the PrV-gB DNA vaccine is functional and induces the production of systemic humoral immune response, and (2) to study whether sIgA against PrV are detected in the saliva of intramuscularly injected pigs. In all cases, anti-PrV IgG and IgA were found in the sera of these pigs; anti-PrV sIgA antibodies were detected in the saliva of 3 out of 4 pigs. To our knowledge, this is the first time that such sIgA antibodies have been detected in the saliva of pigs intramuscularly vaccinated with a DNA vaccine against PrV. Previously, such antibodies were also detected in nasal secretions of pigs intramuscularly injected with a commercial inactivated PrV vaccine (Geskeepur®) (Le Ludec et al., 2016). Unfortunately, the comparisons of the levels of antibodies obtained after the IM injection of our DNA vaccine and Geskeepur® are not possible since the sIgA levels were measured in two different fluids.

IN inoculation of naked DNA vaccine has mainly been described as ineffective in inducing immune responses or protection, with some notable exceptions. For example, Svanholm *et al* reported that significant clinical protection against *Chlamydomydia pneumonia* was obtained after IN immunization of mice with a naked plasmid encoding HSP-60 (Svanholm et al., 2000). Several other studies have reported induction of specific systemic (serum IgG or IgA) or mucosal (sIgA) immune responses against β -galactosidase

(Csaba et al., 2006; Cui and Mumper, 2002), hepatitis B virus (Khatri et al., 2008) or *Streptococcus pneumoniae* (Xu et al., 2011) following IN naked DNA immunizations in mice. Herein, we observed the induction of immune responses after IN inoculation of the naked form of the PrV-gB DNA vaccine in pigs. This inoculation induced both systemic and mucosal humoral immune responses in all the vaccinated pigs (six pigs if we take into account both pig experiments). Even though the number of individuals used was too low to allow significance testing, it seems that systemic anti-PrV IgG and IgA levels is lower following IN inoculation than those measured in the IM group. In contrast, levels of sIgA in the saliva were around the same order of magnitude in the IM and IN groups. In fact, the highest levels of sIgA in the saliva were found for individuals of the IN groups in both pig experiments. But we observed a high inter-individual variations, especially in the IN groups that further limits our ability to interpret the data. That being said, it is noteworthy that all the 6 pigs inoculated with the naked DNA vaccine induced the production of sIgA against PrV in the salivary (instead of 3 out of 4 for the IM group), providing a strong evidence that IN DNA vaccination induces the production of respiratory mucosal immune responses against the targeted pathogen. Cao *et al* that inoculated pigs intranasally with an the attenuated PrV vaccine PrV K61 measured the sIgA titers in saliva around 8 log₂ (Cao et al., 2011), i.e. slightly above the results we obtained here with the naked PrV-gB-based DNA vaccine, which shows that the titers that we obtained are common for the species. Further studies with a higher number of individuals are now necessary to determine if the IN route has a higher potency at inducing sIgA production. In addition, follow-up studies will need to include a thorough optimization procedure to reduce inter-individual variations and enhance the efficacy of this intranasally inoculated DNA vaccine by testing other adjuvants or modifying several other parameters (use of nanovectors, ways to inoculate, etc.).

Most researchers studying IN DNA vaccination combine their DNA vaccines with nanovectors to protect the DNA molecule from mucosal environment degradation until it reaches the cells involved in the development of immune responses. There are many types of nanovectors (for reviews see (Bernocchi et al., 2017; Xu et al., 2014)). For our study, we selected PLGA-PEI nanoparticles. Indeed, PLGA and/or PEI were previously successfully used in IN DNA vaccination in mice (Du et al., 2015; Torrieri-Dramard et al., 2011).

In the present proof of concept study, we selected a DNA/nanovector ratio previously found to be effective to transfect the bronchial lineage HBE-16 cell line *in vitro*. It did not ensure success of *in vivo* IN inoculation but we assumed it would increase chances of success (Ragelle et al., 2014). In association with PLGA-PEI, the duration of mucosal immune response in the saliva induced by the DNA vaccine was longer for two out of three pigs, compared to the three pigs inoculated intranasally with the naked DNA vaccine. This result may be anecdotal, but it reveals that mucosal humoral immune responses might be improved. Clearly, further studies are necessary to optimize the IN DNA vaccine to induce a high and sustained mucosal immune responses. We suggest that such studies should compare the efficiency of PLGA-PEI with other nanovectors, and optimize the other parameters such as the DNA/nanovector ratios, total quantity of DNA, adjuvants and inoculation conditions; inoculation conditions include anesthetized pigs (Janakova et al., 2002) or non-anesthetized pigs (Khatri et al., 2008), the volume of vaccine, number of doses, intervals between the doses, speed of inoculation, and specific devices for inoculation). Only such a thorough and comprehensive approach will allow us to reliably assess the protective immunity induced by IN DNA vaccine strategies.

5. Conclusion

The current study clearly showed that IN inoculation of a naked DNA vaccine encoding PrV-gB induces both a systemic and a mucosal humoral immune response against PrV in

pigs. To the best of our knowledge, this is the first report showing the induction of immune responses following IN inoculation of a naked DNA vaccine in pigs. Some immune response parameters appeared enhanced when the DNA vaccine was combined to PLGA-PEI nanovectors. Even though the inter-individual variability observed indicate that the optimized conditions were not reached in the present study, these results suggest that it is possible to improve DNA vaccine efficacy by varying its composition and inoculation conditions. Based on the promising results presented herein, we encourage future studies to build upon the present results and improve IN DNA vaccination in pigs.

6. Funding

This research was funded by the AgriFoodTransition Tremplin Carnot program (France), DNAINPig research project (convention #10, 2017_00868). L.S. was the recipient of a thesis salary paid by ANSES, Saint-Brieuc Armor Agglomération and Conseil Départemental des Côtes d'Armor (France).

7. Acknowledgements

The authors are grateful to Dr. Mohamed Dia and Dr. Eric Pagot of ZOOPOLE Development (Ploufragan, France), and to the other members of the Pig Production and Experimental Unit (SPPAE) of ANSES (Ploufragan, France) for their technical help during the animal experiments. They also thank Dr. Nolwenn Dheilly (Viral Genetics and Biosafety Unit, ANSES, Ploufragan, France) for the review of the English of the final version of the manuscript.

458

459 **8. Declaration of competing interest**

460 The authors declare that they have no known competing financial interests or personal
461 relationships that could have appeared to influence the work reported in this paper.

462

463 **References**

464 Ai, W., Yue, Y., Xiong, S., Xu, W., 2013. Enhanced protection against pulmonary
465 mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is
466 associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell
467 responses. *Microbiol Immunol* 57, 224-235.

468 Babic, N., Mettenleiter, T.C., Ugolini, G., Flamand, A., Coulon, P., 1994. Propagation
469 of pseudorabies virus in the nervous system of the mouse after intranasal
470 inoculation. *Virology* 204, 616-625.

471 Berchel, M., Le Gall, T., Haelters, J.P., Lehn, P., Montier, T., Jaffres, P.A., 2015.
472 Cationic lipophosphoramidates containing a hydroxylated polar headgroup for
473 improving gene delivery. *Mol Pharm* 12, 1902-1910.

474 Bernocchi, B., Carpentier, R., Betbeder, D., 2017. Nasal nanovaccines. *Int J Pharm*
475 530, 128-138.

476 Cao, D., Li, H., Jiang, Z., Cheng, Q., Yang, Z., Xu, C., Cao, G., Zhang, L., 2011. CpG
477 oligodeoxynucleotide synergizes innate defense regulator peptide for enhancing
478 the systemic and mucosal immune responses to pseudorabies attenuated virus
479 vaccine in piglets in vivo. *Int Immunopharmacol* 11, 748-754.

480 Csaba, N., Garcia-Fuentes, M., Alonso, M.J., 2009. Nanoparticles for nasal
481 vaccination. *Adv Drug Deliv Rev* 61, 140-157.

482 Csaba, N., Sanchez, A., Alonso, M.J., 2006. PLGA:poloxamer and PLGA:poloxamine
483 blend nanostructures as carriers for nasal gene delivery. *J Control Release* 113,
484 164-172.

485 Cui, Z., Mumper, R.J., 2002. Intranasal administration of plasmid DNA-coated
486 nanoparticles results in enhanced immune responses. *J Pharm Pharmacol* 54,
487 1195-1203.

488 Dalmo, R.A., 2018. DNA vaccines for fish: Review and perspectives on correlates of
489 protection. *J Fish Dis* 41, 1-9.

490 Dhakal, S., Renukaradhya, G.J., 2019. Nanoparticle-based vaccine development and
491 evaluation against viral infections in pigs. *Vet Res* 50, 90.

492 Dory, D., Remond, M., Beven, V., Cariolet, R., Backovic, M., Zientara, S., Jestin, A.,
493 2009. Pseudorabies virus glycoprotein B can be used to carry foot and mouth
494 disease antigens in DNA vaccination of pigs. *Antiviral Res* 81, 217-225.

495 Dory, D., Torché, A.M., Béven, V., Blanchard, P., Loizel, C., Cariolet, R., Jestin, A.,
496 2005. Effective protection of pigs against lethal Pseudorabies virus infection after a
497 single injection of low-dose Sindbis-derived plasmids encoding PrV gB, gC and gD
498 glycoproteins. *Vaccine* 23, 3483-3491.

499 Du, L., Li, B., Xu, X., Sun, B., Pang, F., Wen, L., Huang, K., He, K., 2015. Adsorption
500 of a porcine reproductive and respiratory syndrome virus DNA vaccine candidate
501 onto biodegradable nanoparticles improves immunogenicity in mice. *Arch Virol*
502 160, 1543-1547.

503 Dufour, V., 2001. DNA vaccines: new applications for veterinary medicine.
504 *Veterinary Sciences Tomorrow*, 1-20.

505 Eclercy, J., Renson, P., Lebre, A., Hirchaud, E., Normand, V., Andraud, M.,
506 Paboeuf, F., Blanchard, Y., Rose, N., Bourry, O., 2019. A Field Recombinant Strain
507 Derived from Two Type 1 Porcine Reproductive and Respiratory Syndrome Virus
508 (PRRSV-1) Modified Live Vaccines Shows Increased Viremia and Transmission in
509 SPF Pigs. *Viruses* 11.

510 Farris, E., Brown, D.M., Ramer-Tait, A.E., Pannier, A.K., 2016. Micro- and
511 nanoparticulates for DNA vaccine delivery. *Experimental biology and medicine*
512 241, 919-929.

- 513 Gerdts, V., Jöns, A., Makoschey, B., Visser, N., Mettenleiter, C., 1997. Protection of
514 pigs against Aujeszky's disease by DNA vaccination. *J. Gen. Virol.* 78, 2139-2146.
- 515 Gomes, D.C., Pinto, E.F., de Melo, L.D., Lima, W.P., Larraga, V., Lopes, U.G.,
516 Rossi-Bergmann, B., 2007. Intranasal delivery of naked DNA encoding the LACK
517 antigen leads to protective immunity against visceral leishmaniasis in mice. *Vaccine*
518 25, 2168-2172.
- 519 Hass, J., Matuszewski, S., Cieslik, D., Haase, M., 2011. The role of swine as "mixing
520 vessel" for interspecies transmission of the influenza A subtype H1N1: a
521 simultaneous Bayesian inference of phylogeny and ancestral hosts. *Infection,*
522 *genetics and evolution : journal of molecular epidemiology and evolutionary*
523 *genetics in infectious diseases* 11, 437-441.
- 524 Iqbal, M., Lin, W., Jabbal-Gill, I., Davis, S.S., Steward, M.W., Illum, L., 2003. Nasal
525 delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial
526 virus (RSV) induces protective CTL responses in BALB/c mice. *Vaccine* 21,
527 1478-1485.
- 528 Janakova, L., Bakke, H., Haugen, I.L., Berstad, A.K., Hoiby, E.A., Aaberge, I.S.,
529 Haneberg, B., 2002. Influence of intravenous anesthesia on mucosal and systemic
530 antibody responses to nasal vaccines. *Infect Immun* 70, 5479-5484.
- 531 Khatri, K., Goyal, A.K., Gupta, P.N., Mishra, N., Vyas, S.P., 2008. Plasmid DNA
532 loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
533 *Int J Pharm* 354, 235-241.
- 534 Kraehenbuhl, J.P., Neutra, M.R., 2013. Mucosal vaccines: where do we stand?
535 *Current topics in medicinal chemistry* 13, 2609-2628.
- 536 Lawson, L.B., Norton, E.B., Clements, J.D., 2011. Defending the mucosa: adjuvant
537 and carrier formulations for mucosal immunity. *Curr Opin Immunol* 23, 414-420.
- 538 Le Gall, T., Berchel, M., Le Hir, S., Fraix, A., Salaun, J.Y., Ferec, C., Lehn, P., Jaffres,
539 P.A., Montier, T., 2013. Arsonium-containing lipophosphoramides, poly-functional
540 nano-carriers for simultaneous antibacterial action and eukaryotic cell transfection.
541 *Advanced healthcare materials* 2, 1513-1524.

542 Le Luduec, J.B., Debeer, S., Piras, F., Andreoni, C., Boudet, F., Laurent, P.,
 543 Kaiserlian, D., Dubois, B., 2016. Intradermal vaccination with un-adjuvanted
 544 sub-unit vaccines triggers skin innate immunity and confers protective respiratory
 545 immunity in domestic swine. *Vaccine* 34, 914-922.

546 Le Moigne, V., Cariolet, R., Beven, V., Keranflec'h, A., Jestin, A., Dory, D., 2012.
 547 Electroporation improves the immune response induced by a DNA vaccine against
 548 pseudorabies virus glycoprotein B in pigs. *Res Vet Sci* 93, 1032-1035.

549 Liebler-Tenorio, E.M., Pabst, R., 2006. MALT structure and function in farm
 550 animals. *Vet Res* 37, 257-280.

551 Lindberg, M.F., Le Gall, T., Carmoy, N., Berchel, M., Hyde, S.C., Gill, D.R., Jaffres,
 552 P.A., Lehn, P., Montier, T., 2015. Efficient in vivo transfection and safety profile of a
 553 CpG-free and codon optimized luciferase plasmid using a cationic
 554 lipophosphoramidate in a multiple intravenous administration procedure.
 555 *Biomaterials* 59, 1-11.

556 Liu, P., Bai, Y., Jiang, X., Zhou, L., Yuan, S., Yao, H., Yang, H., Sun, Z., 2018. High
 557 reversion potential of a cell-adapted vaccine candidate against highly pathogenic
 558 porcine reproductive and respiratory syndrome. *Vet Microbiol* 227, 133-142.

559 Lycke, N., 2012. Recent progress in mucosal vaccine development: potential and
 560 limitations. *Nat Rev Immunol* 12, 592-605.

561 McGhee, J.R., Fujihashi, K., 2012. Inside the mucosal immune system. *PLoS Biol* 10,
 562 e1001397.

563 Nanda, R.K., Hajam, I.A., Edao, B.M., Ramya, K., Rajangam, M., Chandra Sekar, S.,
 564 Ganesh, K., Bhanuprakash, V., Kishore, S., 2014. Immunological evaluation of
 565 mannosylated chitosan nanoparticles based foot and mouth disease virus DNA
 566 vaccine, pVAC FMDV VP1-OmpA in guinea pigs. *Biologicals* 42, 153-159.

567 Niborski, V., Li, Y., Brennan, F., Lane, M., Torche, A.M., Remond, M., Bonneau, M.,
 568 Riffault, S., Stirling, C., Hutchings, G., Takamatsu, H., Barnett, P., Charley, B.,
 569 Schwartz-Cornil, I., 2006. Efficacy of particle-based DNA delivery for vaccination of
 570 sheep against FMDV. *Vaccine* 24, 7204-7213.

571 Oh, Y.K., Kim, J.P., Hwang, T.S., Ko, J.J., Kim, J.M., Yang, J.S., Kim, C.K., 2001. Nasal
572 absorption and biodistribution of plasmid DNA: an alternative route of DNA
573 vaccine delivery. *Vaccine* 19, 4519-4525.

574 Pabst, O., 2012. New concepts in the generation and functions of IgA. *Nat Rev*
575 *Immunol* 12, 821-832.

576 Pavot, V., Rochereau, N., Genin, C., Verrier, B., Paul, S., 2012. New insights in
577 mucosal vaccine development. *Vaccine* 30, 142-154.

578 Ragelle, H., Riva, R., Vandermeulen, G., Naeye, B., Pourcelle, V., Le Duff, C.S.,
579 D'Haese, C., Nysten, B., Braeckmans, K., De Smedt, S.C., Jerome, C., Preat, V., 2014.
580 Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase
581 stability and efficiency. *J Control Release* 176, 54-63.

582 Shau, M.D., Shih, M.F., Lin, C.C., Chuang, I.C., Hung, W.C., Hennink, W.E.,
583 Cherng, J.Y., 2012. A one-step process in preparation of cationic nanoparticles with
584 poly(lactide-co-glycolide)-containing polyethylenimine gives efficient gene
585 delivery. *Eur J Pharm Sci* 46, 522-529.

586 Somasundaram, C., Takamatsu, H., Andréoni, C., Audonnet, J.-C., Fisher, L.,
587 Lefèvre, F., Charley, B., 1999. Enhanced protective response and immuno-adjuvant
588 effects of porcine GM-CSF on DNA vaccination of pigs against Aujeszky's disease
589 virus. *Vet. Immunol. Immunopathol.* 70, 277-287.

590 Svanholm, C., Bandholtz, L., Castanos-Velez, E., Wigzell, H., Rottenberg, M.E.,
591 2000. Protective DNA immunization against *Chlamydia pneumoniae*. *Scand J*
592 *Immunol* 51, 345-353.

593 Torrieri-Dramard, L., Lambrecht, B., Ferreira, H.L., Van den Berg, T., Klatzmann,
594 D., Bellier, B., 2011. Intranasal DNA vaccination induces potent mucosal and
595 systemic immune responses and cross-protective immunity against influenza
596 viruses. *Mol Ther* 19, 602-611.

597 van Rooij, E.M., Glansbeek, H.L., Hilgers, L.A., te Lintelo, E.G., de Visser, Y.E.,
598 Boersma, W.J., Haagmans, B.L., Bianchi, A.T., 2002. Protective antiviral immune

responses to pseudorabies virus induced by DNA vaccination using dimethyldioctadecylammonium bromide as an adjuvant. *J Virol* 76, 10540-10545.

van Rooij, E.M., Haagmans, B.L., Glansbeek, H.L., de Visser, Y.E., de Bruin, M.G., Boersma, W., Bianchi, A.T., 2000. A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection. *Vet Immunol Immunopathol* 74, 121-136.

Wang, S., Liu, H., Zhang, X., Qian, F., 2015. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. *Protein & cell* 6, 480-503.

Xu, J., Dai, W., Wang, Z., Chen, B., Li, Z., Fan, X., 2011. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by *Streptococcus pneumoniae*. *Clin Vaccine Immunol* 18, 75-81.

Xu, Y., Yuen, P.W., Lam, J.K., 2014. Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. *Pharmaceutics* 6, 378-415.

Yoon, H.A., Han, Y.W., Aleyas, A.G., George, J.A., Kim, S.J., Kim, H.K., Song, H.J., Cho, J.G., Eo, S.K., 2008. Protective immunity induced by systemic and mucosal delivery of DNA vaccine expressing glycoprotein B of pseudorabies virus. *J Microbiol Biotechnol* 18, 591-599.

Figure legends:

Figure 1: Schematic representation of the animal immunization experiments.

(A) Assessment of immune potentials in pigs inoculated intranasally with a naked PrV-gB DNA vaccine. **(B)** Assessment of immune potentials in pigs inoculated intranasally with a formulated PrV-gB DNA vaccine.

Figure 2: ELISA determination of systemic IgG antibody levels against PrV after inoculation with a naked PrV-gB-based DNA vaccine.

Pigs were inoculated three times with a naked pcDNA3-gB DNA vaccine, as indicated by the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. IgG titers of the two non-inoculated pigs and the three pigs inoculated by the IM route are indicated in **(A)**. IgG titers of the three pigs inoculated by the IN route are indicated in **(B)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.

Figure 3: ELISA determination of salivary sIgA antibody levels against PrV after inoculation with a naked PrV-gB-based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine at ten-day intervals. Pig saliva samples were collected at days 29 and 37 after the first inoculation (dpi). Black bars correspond to 29 dpi and dashed bars to 37 dpi. Saliva dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales.

Figure 4: *In vitro* toxicity and cell transfection potentials of naked and PLGA-PEI associated plasmids.

HBE-16 cells were incubated with 1 µg of naked plasmid pTG11033 (Naked DNA), 1 µg of plasmid DNA pTG11033 adsorbed onto premade PLGA-PEI nanoparticles at a weight to weight ratio of 12 (PLGA-PEI-DNA). Cell viabilities (**A**) and luciferase expressions (**B**) were measured at 72 hours post-transfection. The untransfected cell condition served as a reference level (NT cells) corresponding to 100% viability (dashed line) (A) or to luciferase base level (B). In the latter case, the values expressed in relative light units (RLUs) per protein mg measured in the cell lysates are indicated. Mean results of three independent experiments are presented \pm SD. Significant differences between each condition and their respective controls were determined with the non-parametric Mann–Whitney test (ab, $p < 0.05$).

Figure 5: ELISA determination of systemic IgG antibody levels against PrV after intranasal inoculation with a naked or PLGA-PEI associated PrV-gB-based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. Results for the three pigs inoculated with naked pcDNA3-gB are indicated in (**A**). Results for the three pigs inoculated with PLGA-PEI-pcDNA3-gB are indicated in (**B**). Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.

Figure 6: ELISA determination of salivary sIgA antibody levels against PrV after inoculation with a naked or PLGA-PEI associated PrV-gB based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig saliva samples were collected every 8-10 days throughout the pig experiment. Results for the four non-inoculated pigs and the single animal inoculated through the IM route are indicated in **(A)**. Results for the three pigs inoculated by the IN route with naked pcDNA3-gB are indicated in **(B)**. Results for the three pigs inoculated by the IN route with PLGA-PEI-pcDNA3-gB are indicated in **(C)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls ± 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.




Figure 1: Schematic representation of the animal immunization experiments.

(A) Assessment of immune potentials in pigs inoculated intranasally with a naked PrV-gB DNA vaccine. **(B)** Assessment of immune potentials in pigs inoculated intranasally with a formulated PrV-gB DNA vaccine.




Figure 2: ELISA determination of systemic IgG antibody levels against PrV after inoculation with a naked PrV-gB-based DNA vaccine.

Pigs were inoculated three times with a naked pcDNA3-gB DNA vaccine, as indicated by the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. IgG titers of the two non-inoculated pigs and the three pigs inoculated by the IM route are indicated in **(A)**. IgG titers of the three pigs inoculated by the IN route are indicated in **(B)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.




Figure 3: ELISA determination of salivary sIgA antibody levels against PrV after inoculation with a naked PrV-gB-based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine at ten-day intervals. Pig saliva samples were collected at days 29 and 37 after the first inoculation (dpi). Black bars correspond to 29 dpi and dashed bars to 37 dpi. Saliva dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales.





Figure 4: *In vitro* toxicity and cell transfection potentials of naked and PLGA-PEI associated plasmids.

HBE-16 cells were incubated with 1 μ g of naked plasmid pTG11033 (Naked DNA), 1 μ g of plasmid DNA pTG11033 adsorbed onto premade PLGA-PEI nanoparticles at a weight to weight ratio of 12 (PLGA-PEI-DNA). Cell viabilities (**A**) and luciferase expressions (**B**) were measured at 72 hours post-transfection. The untransfected cell condition served as a reference level (NT cells) corresponding to 100% viability (dashed line) (**A**) or to luciferase base level (**B**). In the latter case, the values expressed in relative light units (RLUs) per protein mg measured in the cell lysates are indicated. Mean results of three independent experiments are presented \pm SD. Significant differences between each condition and their respective controls were determined with the non-parametric Mann–Whitney test (ab, $p < 0.05$).

A



B




Figure 5: ELISA determination of systemic IgG antibody levels against PrV after intranasal inoculation with a naked or PLGA-PEI associated PrV-gB-based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. Results for the three pigs inoculated with naked pcDNA3-gB are indicated in **(A)**. Results for the three pigs inoculated with PLGA-PEI-pcDNA3-gB are indicated in **(B)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.




Figure 6: ELISA determination of salivary sIgA antibody levels against PrV after inoculation with a naked or PLGA-PEI associated PrV-gB based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig saliva samples were collected every 8-10 days throughout the pig experiment. Results for the four non-inoculated pigs and the single animal inoculated through the IM route are indicated in **(A)**. Results for the three pigs inoculated by the IN route with naked pcDNA3-gB are indicated in **(B)**. Results for the three pigs inoculated by the IN route with PLGA-PEI-pcDNA3-gB are indicated in **(C)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.